About Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist used in metabolic research. Supplied as a lyophilized powder for laboratory studies investigating dual incretin receptor activation, insulin-related signaling pathways, and glucose homeostasis mechanisms in controlled experimental models. Each batch undergoes analytical verification for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: >95-99 (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
Recent research on Tirzepatide: Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
Read Full Study on PubMedSimultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series.
Recent research on Tirzepatide: Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series.
Read Full Study on PubMedAdditional Studies
Inappropriate use of GLP-1-based antiobesity medications: beyond appropriate drug use toward appropriate weight reduction.
Recent research on Tirzepatide: Inappropriate use of GLP-1-based antiobesity medications: beyond appropriate drug use toward appropriate weight reduction.
Read on PubMedTirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases.
Recent research on Tirzepatide: Tirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases.
Read on PubMedGlucagon-like receptor-1 agonists and impotence: A meta-analysis.
Recent research on Tirzepatide: Glucagon-like receptor-1 agonists and impotence: A meta-analysis.
Read on PubMedPancreatic-liver crosstalk, novel molecular mediators, and 2025 therapeutic breakthroughs.
Recent research on Tirzepatide: Pancreatic-liver crosstalk, novel molecular mediators, and 2025 therapeutic breakthroughs.
Read on PubMedOrforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.
Recent research on Tirzepatide: Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.
Read on PubMedEffect of GLP-1 receptor agonist on nutrient intake: A narrative review.
Recent research on Tirzepatide: Effect of GLP-1 receptor agonist on nutrient intake: A narrative review.
Read on PubMedRelated Research
Purchase Tirzepatide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.